Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Lee, Matthew M.Y.; Kristensen, Søren L.; Gerstein, Hertzel C.; McMurray, John J.V.; Sattar, Naveed
• Is Part Of: Diabetes & metabolic syndrome. Volume 16:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: Diabetes -- GLP-1 receptor agonists -- Cardiovascular disease; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2021.102382
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background and aims: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings. Methods: We meta-analysed its results with eight prior GLP-1 receptor agonists trials. Results: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81–0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83–0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials. Conclusion: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650. Highlights: The FREEDOM Cardiovascular Outcomes trial results were recently published. Its results appear different to other GLP-1 receptor agonist outcome trials in a trial meta-analysis. This and other concerns mean FREEDOM should not influence current perceptions about the benefits of GLP-1 receptor agonists.